Helical tomotherapy of spinal chordomas: French Multicentric, retrospective study of a cohort of 30 cases. Issue 1 (December 2017)

• Record Type: Journal Article
• Authors: Bobin, Maxime; Zacharatou, Christina; Sargos, Paul; Brouste, Véronique; Lisbona, Albert; Mahé, Marc-André; Noël, Georges; Halley, Amandine; Feuvret, Loïc; Gras, Louis; Hoppe, Stéphanie; de Figueiredo, Bénédicte; Kantor, Guy
• Is Part Of: Radiation oncology. Volume 12:Issue 1(2017)
• Page Start: 1
• Page End: 9
• Publication Date: 2017-12
• Subjects: Helical tomotherapy -- Spinal chordomas -- Survival rates -- Local control; Cancer -- Radiotherapy -- Periodicals; 616.9940642
• DOI: 10.1186/s13014-017-0768-1
• Languages: English
• ISSNs: 1748-717X

Abstract

Abstract Purpose To evaluate the efficacy and toxicity of helical tomotherapy (HT) in the management of spine chordomas when proton therapy is unavailable or non-feasible. Methods and materials Between 2007 and 2013, 30 patients with biopsy-proven chordomas were treated by HT in five French institutions. Information regarding local control (LC), overall survival (OS), progression-free survival (PFS) and metastasis-free survival (MFS) was collected. Clinical efficacy, toxicity and treatment quality were evaluated. Results Two-year actuarial LC, OS, PFS and MFS were 69.9%, 96.7%, 61.2% and 76.4%, respectively. HT treatments were well tolerated and no Grade 4–5 toxicities were observed. HT permitted the delivery of a mean dose of 68 Gy while respecting organ at risk (OAR) dose constraints, in particular in the spinal cord and cauda equina. Conclusions This multicentric, retrospective study demonstrated the feasibility of HT in the treatment of spine chordomas, in the absence of hadron therapy.